Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hairy Cell Leukemia - Overview
Hairy Cell Leukemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hairy Cell Leukemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hairy Cell Leukemia - Companies Involved in Therapeutics Development
AbbVie Inc
Ascentage Pharma Group Intertiol
AstraZeneca Plc
Autolus Therapeutics Plc
Bristol-Myers Squibb Co
Eureka Therapeutics Inc
F. Hoffmann-La Roche Ltd
Incyte Corp
Jecho Biopharmaceuticals Co Ltd
MacroGenics Inc
Mediolanum farmaceutici SpA
Mustang Bio Inc
Novartis AG
Sorrento Therapeutics Inc
Wuhan Bio-Raid Biotechnology Co Ltd
Xi’An Yufan Biotechnology Co Ltd
Xynomic Pharmaceuticals Holdings Inc
Hairy Cell Leukemia - Drug Profiles
abivertinib maleate - Drug Profile
Product Description
Mechanism Of Action
History of Events
acalabrutinib maleate - Drug Profile
Product Description
Mechanism Of Action
History of Events
APG-2575 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AUTO-1NG - Drug Profile
Product Description
Mechanism Of Action
History of Events
CDMO-002 - Drug Profile
Product Description
Mechanism Of Action
cobimetinib fumarate - Drug Profile
Product Description
Mechanism Of Action
History of Events
dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile
Product Description
Mechanism Of Action
History of Events
dezapelisib - Drug Profile
Product Description
Mechanism Of Action
History of Events
ELB-021 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ET-019002 - Drug Profile
Product Description
Mechanism Of Action
GEM-155 - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Target CD19 for Leukemia or Lymphoma - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Target CD19 for Lymphoma and Leukemia - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Target CD19 for Oncology - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Target CD19 for Oncology - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Target CD19 for Oncology - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Target CD20 for Oncology - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Target CD22 for Oncology - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Target CD22 for Oncology - Drug Profile
Product Description
Mechanism Of Action
History of Events
ibrutinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
interferon alfa-2b - Drug Profile
Product Description
Mechanism Of Action
itacitinib adipate - Drug Profile
Product Description
Mechanism Of Action
History of Events
MB-106 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MGD-024 - Drug Profile
Product Description
Mechanism Of Action
moxetumomab pasudotox - Drug Profile
Product Description
Mechanism Of Action
History of Events
obinutuzumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
Onureg - Drug Profile
Product Description
Mechanism Of Action
History of Events
parsaclisib - Drug Profile
Product Description
Mechanism Of Action
History of Events
vemurafenib - Drug Profile
Product Description
Mechanism Of Action
History of Events
XP-102 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Hairy Cell Leukemia - Dormant Projects
Hairy Cell Leukemia - Discontinued Products
Hairy Cell Leukemia - Product Development Milestones
Featured News & Press Releases
Jul 21, 2021: Study: Ibrutinib effective treatment for difficult to treat forms of hairy cell leukemia
May 19, 2021: ESMO: BRAF inhibitor and Rituximab for the magement of refractory or relapsed HCL
Dec 10, 2020: CHMP adopts a positive opinion for the medicil product Lumoxiti for the treatment of relapsed or refractory hairy cell leukaemia
Jan 02, 2020: The European Medicines Agency accepts the regulatory submission for Lumoxiti in relapsed or refractory hairy cell leukemia
Dec 08, 2019: Inte Pharma highlights FDA-approved Lumoxiti at ASH 2019
Nov 07, 2019: Inte Pharma to share new long-term data on Lumoxiti at 2019 American Society of Hematology annual meeting
May 08, 2019: A patient’s 10-year journey to moxetumomab for hairy cell leukemia
Mar 12, 2019: Inte Pharma announces the appointment of Jennifer Butler appointed as executive vice president, general mager, US
Nov 27, 2018: AstraZeneca to present on Lumoxiti 2018 American Society of Hematology Annual Meeting
Nov 02, 2018: Novartis to present data on Dabrafenib and Trametinib combition at 2018 ASH annual meeting
Sep 17, 2018: AstraZeneca’s Lumoxiti secures FDA nod to treat hairy cell leukaemia
Jun 02, 2018: Moxetumomab Pasudotox Pivotal Data in Patients with Previously-Treated Hairy Cell Leukemia Presented at the 2018 ASCO Meeting
Apr 03, 2018: US FDA Accepts Biologics License Application for Moxetumomab Pasudotox in Hairy Cell Leukaemia
Oct 09, 2016: ESMO 2016: Vemurafenib Shows Clinical Benefit in Diverse BRAF V600-Mutated Tumours
May 16, 2013: AstraZeneca’s MedImmune Enrolls First Patient In Phase III Leukemia Trial Of Moxetumomab Pasudotox
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Hairy Cell Leukemia, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Hairy Cell Leukemia, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Hairy Cell Leukemia - Pipeline by AbbVie Inc, 2022
Hairy Cell Leukemia - Pipeline by Ascentage Pharma Group International, 2022
Hairy Cell Leukemia - Pipeline by AstraZeneca Plc, 2022
Hairy Cell Leukemia - Pipeline by Autolus Therapeutics Plc, 2022
Hairy Cell Leukemia - Pipeline by Bristol-Myers Squibb Co, 2022
Hairy Cell Leukemia - Pipeline by Eureka Therapeutics Inc, 2022
Hairy Cell Leukemia - Pipeline by F. Hoffmann-La Roche Ltd, 2022
Hairy Cell Leukemia - Pipeline by Incyte Corp, 2022
Hairy Cell Leukemia - Pipeline by Jecho Biopharmaceuticals Co Ltd, 2022
Hairy Cell Leukemia - Pipeline by MacroGenics Inc, 2022
Hairy Cell Leukemia - Pipeline by Mediolanum farmaceutici SpA, 2022
Hairy Cell Leukemia - Pipeline by Mustang Bio Inc, 2022
Hairy Cell Leukemia - Pipeline by Novartis AG, 2022
Hairy Cell Leukemia - Pipeline by Sorrento Therapeutics Inc, 2022
Hairy Cell Leukemia - Pipeline by Wuhan Bio-Raid Biotechnology Co Ltd, 2022
Hairy Cell Leukemia - Pipeline by Xi’An Yufan Biotechnology Co Ltd, 2022
Hairy Cell Leukemia - Pipeline by Xynomic Pharmaceuticals Holdings Inc, 2022
Hairy Cell Leukemia - Dormant Projects, 2022
Hairy Cell Leukemia - Discontinued Products, 2022